This study is designed to provide safety and efficacy data to support the development of CP-690,550 in patients with moderate to severe rheumatoid arthritis on background of methotrexate.
Phase 3
Completed
- Conditions
- Health Condition 1: null- Arthritis, Rheumatoid
- Registration Number
- CTRI/2011/091/000575
- Lead Sponsor
- Pfizer Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 750
Inclusion Criteria
1. Ages Eligible for Study: 18 Years and older
2.Genders Eligible for Study: Both
3.Accepts Healthy Volunteers: No
4.Adults with moderate to severe rheumatoid arthritis on a stable dose of methotrexate
There is no upper age limit for inclusion criteria for this trial
Exclusion Criteria
Pregnancy, severe or unstable medical conditions, including serious infections (e.g., tuberculosis, HIV), clinically significant laboratory abnormalities (transaminases, hemoglobin), or use of prohibited concomitant medications (all DMARDs except methotrexate).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method